Imagine a lock that is starting to be picked by a clever thief; that is what is happening with current malaria drugs. This project adds a second, different kind of lock to the door to keep the parasite out. By combining two proven medicines, it stops the disease more effectively and prevents it from spreading to others.
Current malaria treatments are facing the threat of drug-resistant mutants in Africa. There is an urgent need for more efficient therapies to prevent a spike in child mortality.
A Phase III clinical trial protocol and a triple-therapy regimen (AL+AP) tested for safety and cure rate in children.
If you are a generic drug manufacturer dealing with the rise of drug-resistant malaria strains — this project developed a triple-therapy combination (AL+AP) that protects the lifespan of existing treatments. This allows for the creation of a new, high-efficacy product line for the African market.
If you are a medical supply distributor dealing with the need for more efficient pediatric treatments — this project tested a regimen in 1,664 children. This provides the clinical evidence needed to scale the distribution of a first-candidate regimen for when resistance spreads.
If you are a biotech company dealing with the lack of infrastructure to measure transmission reduction — this project developed infrastructure to support the assessment of transmission-blocking activity. This can be used to validate the efficacy of other new malaria interventions.
Based on available project data, there is no information regarding the cost or pricing of the AL+AP therapy.
The project is conducting a Phase III clinical trial with 1,664 children, which is a critical step toward industrial-scale deployment and regulatory approval.
Based on available project data, specific IP or licensing agreements are not mentioned; however, the project uses existing medicines (AL and AP).
The project period is from 2024-01-01 to 2025-12-31, focusing on clinical evaluation before deployment.
It is designed as a replacement or supplement to current Artemisinin-based combination therapies (ACTs) to mitigate the risk of resistance.
The consortium is research-heavy, consisting of 7 partners across 7 countries. It is led by the Bernhard Nocht Institute for Tropical Medicine (DE) and includes a 14% industry ratio (1 company), indicating a strong focus on clinical validation and academic research over immediate commercialization. The geographical spread (BF, BJ, DE, FR, GA, GH, ML) ensures high regional relevance for the African market.
Contact Bernhard Nocht Institut fuer Tropenmedizin in Germany
Contact us to explore licensing opportunities for the AL+AP regimen.
